Amyotrophic lateral sclerosis: a long preclinical period?
- 19 March 2014
- journal article
- review article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 85 (11), 1232-1238
- https://doi.org/10.1136/jnnp-2013-307135
Abstract
The onset of amyotrophic lateral sclerosis (ALS) is conventionally considered as commencing with the recognition of clinical symptoms. We propose that, in common with other neurodegenerations, the pathogenic mechanisms culminating in ALS phenotypes begin much earlier in life. Animal models of genetically determined ALS exhibit pathological abnormalities long predating clinical deficits. The overt clinical ALS phenotype may develop when safety margins are exceeded subsequent to years of mitochondrial dysfunction, neuroinflammation or an imbalanced environment of excitation and inhibition in the neuropil. Somatic mutations, the epigenome and external environmental influences may interact to trigger a metabolic cascade that in the adult eventually exceeds functional threshold. A long preclinical and subsequent presymptomatic period pose a challenge for recognition, since it offers an opportunity for protective and perhaps even preventive therapeutic intervention to rescue dysfunctional neurons. We suggest, by analogy with other neurodegenerations and from SOD1 ALS mouse studies, that vulnerability might be induced in the perinatal period.Keywords
This publication has 103 references indexed in Scilit:
- Infectious Agents and NeurodegenerationMolecular Neurobiology, 2012
- Somatic mutations in aging, cancer and neurodegenerationMechanisms of Ageing and Development, 2012
- Biology of Mitochondria in Neurodegenerative DiseasesProgress in Molecular Biology and Translational Science, 2012
- Epigenetic mechanisms in developmental programming of adult diseaseDrug Discovery Today, 2011
- Astrocytes from familial and sporadic ALS patients are toxic to motor neuronsNature Biotechnology, 2011
- Somatic evolutionary genomics: Mutations during development cause highly variable genetic mosaicism with risk of cancer and neurodegenerationProceedings of the National Academy of Sciences of the United States of America, 2010
- Non–cell autonomous toxicity in neurodegenerative disorders: ALS and beyondThe Journal of cell biology, 2009
- Mitochondrial fragmentation in neurodegenerationNature Reviews Neuroscience, 2008
- Mitochondrial Medicine for Aging and Neurodegenerative DiseasesNeuroMolecular Medicine, 2008
- Non–cell autonomous effect of glia on motor neurons in an embryonic stem cell–based ALS modelNature Neuroscience, 2007